Daliresp
roflumilast
Roflumilast
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
What Daliresp is and what it is used for
What you need to know before you take Daliresp
How to take Daliresp
Possible side effects
How to store Daliresp
Medicinal product no longer authorised
Contents of the pack and other information
Daliresp contains the active substance roflumilast, which is an anti-inflammatory medicine called phosphodiesterase-4 inhibitor. Roflumilast reduces the activity of phosphodiesterase-4, a protein occurring naturally in body cells. When the activity of this protein is reduced, there is less inflammation in the lungs. This helps to stop narrowing of airways occurring in chronic obstructive pulmonary disease (COPD). Thus Daliresp eases breathing problems.
Daliresp is used for maintenance treatment of severe COPD in adults who in the past had frequent worsening of their COPD symptoms (so-called exacerbations) and who have chronic bronchitis. COPD is a chronic disease of the lungs that results in tightening of the airways (obstruction) and swelling and irritation of the walls of the small air passages (inflammation). This leads to symptoms such as coughing, wheezing, chest tightness or difficulty in breathing. Daliresp is to be used in addition to bronchodilators.
if you are allergic to roflumilast or any of the other ingredients of this medicine (listed in section 6)
if you have moderate or severe liver problems.
Talk to your doctor or pharmacist before taking Daliresp
Suddenattackofbreathlessness
Daliresp is not intended for the treatment of a sudden attack of breathlessness (acute bronchospasms).
In order to relieve a sudden attack of breathlessness it is very important that your doctor provides you with another medicine to be available to you at all times that can cope with such an attack. Daliresp will not help you in this situation.
Body weight
You should check your body weight on a regular basis. Talk to your doctor if, while taking this medicine, you observe an unintentional loss of body weight (not related to a diet or exercise programme).
Otherdiseases
Daliresp is not recommended if you have one or more of the following diseases:
severe immunological diseases such as HIV infection, multiple sclerosis (MS), lupus erythematosus (LE) or progressive multifocal leukoencephalopathy (PML)
severe acute infectious diseases such as tuberculosis, or acute hepatitis
cancer (except basal-cell carcinoma, a slow-growing type of skin cancer)
or severe impairment of the heart function
There is a lack of relevant experience with Daliresp under these conditions. You should talk to your doctor, if you are diagnosed with any of these diseases.
Experience is also limited in patients with a previous diagnosis of tuberculosis, viral hepatitis, herpes viral infection or herpes zoster. Please talk to your doctor if you have one of these diseases.
Symptomsyoushouldbeawareof
Medicinal product no longer authorised
You may experience diarrhoea, nausea, abdominal pain or headache during the first weeks of treatment with Daliresp. Talk to your doctor if these side effects do not resolve within the first weeks of treatment.
Daliresp is not recommended in patients with a history of depression associated with suicidal thinking or behaviour. You may also experience sleeplessness, anxiety, nervousness, or depressive mood. Before starting treatment with Daliresp, inform your doctor if you are suffering from any symptoms of this
kind and of any additional medicines you may take since some of those could increase the probability of these side effects. You or your caregiver should also immediately inform your doctor of any changes in behaviour or mood and of any suicidal thoughts you may have.
Daliresp should not be used by children and adolescents under 18 years of age.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, especially the following:
a medicine containing theophylline (a medicine to treat respiratory diseases), or
a medicine used for treatment of immunological diseases, such as methotrexate, azathioprine, infliximab, etanercept, or oral corticosteroids to be taken long-term.
a medicine containing fluvoxamine (a medicine to treat anxiety disorders and depression), enoxacin (a medicine to treat bacterial infections) or cimetidine (a medicine to treat stomach ulcers or heartburn).
The effect of Daliresp may be reduced if taken together with rifampicin (an antibiotic medicine) or with phenobarbital, carbamazepine or phenytoin (medicines usually prescribed for the treatment of epilepsy). Ask your doctor for advice.
Daliresp may be taken with other medicines used in the treatment of COPD such as inhaled or oral corticosteroids or bronchodilators. Do not stop taking these medicines or reduce their dose unless advised by your doctor.
Do not take Daliresp if you are or plan to become pregnant, think you may be pregnant, or are
breast-feeding. You should not become pregnant during treatment with this medicine and should use an effective method of contraception during therapy, because Daliresp may be harmful for the unborn baby.
Daliresp has no influence on the ability to drive and use machines.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose is one 500 micrograms tablet once daily.
Swallow the tablet with some water. You may take this medicine with or without food. Take the tablet at the same time every day.
You may need to take Daliresp for several weeks to achieve its beneficial effect.
Medicinal product no longer authorised
If you have taken more tablets than you should, you may experience the following symptoms: headache, nausea, diarrhoea, dizziness, throbbing of your heart, light-headedness, clamminess and low blood pressure. Tell your doctor or pharmacist straight away. If possible take your medicine and this leaflet with you.
If you forget to take a tablet at the usual time, take the tablet as soon as you remember on the same day. If on one day you have forgotten to take a tablet of Daliresp, just carry on the next day with the next tablet as usual. Continue taking your medicine at the usual times. Do not take a double dose to make up for a forgotten dose.
It is important to continue taking Daliresp for as long as prescribed by your doctor, even when you have no symptoms, in order to maintain control of your lung function.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You may experience diarrhoea, nausea, stomach ache or headache during the first weeks of treatment with Daliresp. Talk to your doctor if these side effects do not resolve within the first weeks of treatment.
Some side effects could be serious. In clinical studies and post-marketing experience, rare instances of suicidal thinking and behaviour (including suicide) were reported. Please notify your doctor immediately
of any suicidal thoughts you may have. You may also experience sleeplessness (common), anxiety (uncommon), nervousness (rare), panic attack (rare) or depressive mood (rare).
In uncommon cases allergic reactions may occur. Allergic reactions may affect the skin and in rare cases cause swelling of the eyelids, face, lips and tongue, possibly leading to difficulties in breathing and/or a drop in blood pressure and accelerated heartbeat. In case of an allergic reaction, stop taking Daliresp and contact your doctor immediately, or go immediately to the emergency department in the nearest hospital. Take all your medicines and this leaflet with you and provide full information of your current medications.
Othersideeffectsincludethefollowing:
diarrhoea, nausea, stomach ache
weight decrease, decreased appetite
headache
trembling, sensation of spinning head (vertigo), dizziness
sensation of rapid or irregular heartbeat (palpitations)
gastritis, vomiting
reflux of stomach acid to the gullet (acid regurgitations), indigestion
rash
muscle pain, muscle weakness or cramps
back pain
feeling of weakness or tiredness, feeling unwell.
Medicinal product no longer authorised
male breast enlargement
decreased sense of taste
respiratory tract infections (excluding pneumonia)
bloody stools, constipation
elevation of liver or muscle enzymes (seen in blood tests)
wheals (urticaria).
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via thenationalreportingsystemlistedin AppendixV. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is roflumilast. Each film-coated tablet (tablet) contains 500 micrograms roflumilast.
The other ingredients are:
Core: lactose monohydrate, maize starch, povidone (K90), magnesium stearate,
Coating: hypromellose, Macrogol 4000, titanium dioxide (E171), and iron oxide yellow (E172).
Daliresp 500 micrograms film-coated tablets are yellow, D-shaped film-coated tablets, embossed with 'D' on one side.
Each pack contains 10, 30, or 90 film-coated tablets. Not all pack sizes may be marketed.
AstraZeneca AB
SE-151 85 Södertälje Sweden
Takeda GmbH
Production site Oranienburg Lehnitzstraße 70-98
Medicinal product no longer authorised
16515 Oranienburg Germany
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
UAB AstraZeneca Lietuva Tel: +370 5 2660550
АстраЗенека България ЕООД Тел.: +359 24455000
AstraZeneca Czech Republic s.r.o. Tel: +420 222 807 111
AstraZeneca A/S
Tlf: +45 43 66 64 62
Associated Drug Co. Ltd Tel: +356 2277 8000
AstraZeneca BV
Tel: +31 79 363 2222
AstraZeneca
Tel: +372 6549 600
AstraZeneca AS
Tlf: +47 21 00 64 00
AstraZeneca A.E.
Τηλ: +30 210 6871500
AstraZeneca Österreich GmbH Tel: +43 1 711 31 0
Laboratorio Tau, S.A. Tel: +34 91 301 91 00
AstraZeneca Pharma Poland Sp. z o.o. Tel.: +48 22 245 73 00
AstraZeneca
Tél: +33 1 41 29 40 00
AstraZeneca Produtos Farmacêuticos, Lda. Tel: +351 21 434 61 00
AstraZeneca Pharma SRL Tel: +40 21 317 60 41
AstraZeneca Pharmaceuticals (Ireland) Ltd Tel: +353 1609 7100
AstraZeneca UK Limited Tel: +386 1 51 35 600
Vistor hf.
Sími: +354 535 7000
Simesa S.p.A.
Tel: +39 02 9801 1
AstraZeneca Oy
Puh/Tel: +358 10 23 010
Medicinal product no longer authorised
Αλέκτωρ Φαρµακευτική Λτδ Τηλ: +357 22490305
AstraZeneca AB
Tel: +46 8 553 26 000
SIA AstraZeneca Latvija Tel: +371 67377100